# Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

> **NCT03181984** · PHASE4 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 501 (actual)

## Conditions studied

- Port-Wine Stain

## Interventions

- **DRUG:** Hemoporfin

## Key facts

- **NCT ID:** NCT03181984
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-31
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181984, "Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03181984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*